	As of			As of
	March 31, 2019			December 31, 2018
Land	$	1,210		$	1,210
Building		14,913			180,094
Computer equipment and software		6,474			6,365
Office equipment		5,788			5,584
Laboratory equipment		39,442			35,693
Leasehold improvements		12,325			183
Construction-in-progress		60,766			46,669
Total property, plant and equipment		140,918			275,798
Less accumulated depreciation and amortization		(26,888	)		(29,176	)
Property, plant and equipment, net	$	114,030		$	246,622

In November 2017, the Company acquired a manufacturing facility, which is in the process of construction, in Durham, North Carolina for the future manufacture of lentiviral vector for the Company’s gene therapies. Construction-in-progress as of March 31, 2019 and December 31, 2018 includes $47.1 million and $40.4 million, respectively, related to the North Carolina manufacturing facility. During the three months ended March 31, 2019, the Company placed an additional $2.7 million of the North Carolina manufacturing facility into service and began to depreciate the assets. Total building assets placed into service related to the North Carolina manufacturing facility as of March 31, 2019 and December 31, 2018 were $14.9 million and $12.2 million, respectively.

As a result of the adoption of ASU 2016-02, the Company de-recognized $156.0 million of the building asset and $6.7 million of accumulated depreciation related to its corporate headquarters at 60 Binney Street. Prior to the adoption of ASU 2016-02, the Company classified leasehold improvements associated with the 60 Binney Street building as building. Subsequent to the adoption of ASU 2016-02, the leasehold improvements associated with the 60 Binney Street building are classified as leasehold improvements. Please refer to Note 2, “Basis of presentation, principles of consolidation and significant accounting policies” and Note 7, “Leases” for further information.